Market Overview

UPDATE: Morgan Stanley Initiates NPS Pharmaceuticals at Overweight on Portfolio Quality

Related NPSP
UPDATE: Canaccord Genuity Assumes Coverage on NPS Pharmaceuticals on Recent Market Weakness
Benzinga's Top Initiations

Morgan Stanley initiated coverage on NPS Pharmaceuticals (NASDAQ: NPSP) with an Overweight rating and a $17 price target

Morgan Stanley commented, "NPS has two novel, late stage assets that we believe have key characteristics that to us indicate a high chance of commercial success despite the increasingly difficult reimbursement environment: a) strong efficacy and safety with a good disease impact, b) target diseases with a high unmet need and high acuity, and c) a competitive/unique drug profile. We believe the Street undervalues these novel assets, removing the long term leverage from this focused, orphan model."

NPS Pharmaceuticals closed at $9.52 on Wednesday.

Posted-In: Morgan StanleyAnalyst Color Initiation Intraday Update Analyst Ratings

 

Most Popular

Related Articles (NPSP)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free